Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP114688.RAJNKdukMKQSOUQXuR-SqNdazWp_r2FjRuO7Krt5Zdwq8130_assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP114688.RAJNKdukMKQSOUQXuR-SqNdazWp_r2FjRuO7Krt5Zdwq8130_provenance.
• NP115482.RAu1i_9gb0MigkNqFAlcG8ESKPK7FSL4IWjP0JPSjrWXs130_assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP115482.RAu1i_9gb0MigkNqFAlcG8ESKPK7FSL4IWjP0JPSjrWXs130_provenance.
• NP625226.RAopxs3MlVbXYQaYCqs4irBSBYrn2Rw-O-xvcWKZudLG0130_assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625226.RAopxs3MlVbXYQaYCqs4irBSBYrn2Rw-O-xvcWKZudLG0130_provenance.
• assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP589700.RAIT0SqZiqQxwiim3qtaC0s_viD6cwT7KowgVQ_qE33Ug130_assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP589700.RAIT0SqZiqQxwiim3qtaC0s_viD6cwT7KowgVQ_qE33Ug130_provenance.
• NP661240.RAHIQUsyYRSjt5bRGo-Z7_-vU5GoM61Ma5OK_g3vEjtPA130_assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP661240.RAHIQUsyYRSjt5bRGo-Z7_-vU5GoM61Ma5OK_g3vEjtPA130_provenance.
• assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP272264.RAsV96gEKz8w6EmMcUMJ9EkJf-LvxppmXlzhyrysAbzLo130_assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP272264.RAsV96gEKz8w6EmMcUMJ9EkJf-LvxppmXlzhyrysAbzLo130_provenance.
• NP272443.RAiHL5YzS3L5WkfwB41XREeGX-iwKiMRg1HDsYIjQycRY130_assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP272443.RAiHL5YzS3L5WkfwB41XREeGX-iwKiMRg1HDsYIjQycRY130_provenance.
• NP414416.RAAMCGBYykpMuHcD6LdnvZWqimo2mWvE7ukWZr-mmevFo130_assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP414416.RAAMCGBYykpMuHcD6LdnvZWqimo2mWvE7ukWZr-mmevFo130_provenance.
• NP414419.RAXmgCyrmgC_E3q7gfND2I28M2Tit5L3dwA36xyfLGEh0130_assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP414419.RAXmgCyrmgC_E3q7gfND2I28M2Tit5L3dwA36xyfLGEh0130_provenance.
• NP743085.RAEJ1y79uUCpSzYofU2UNhJJ_HmXfRgvoeVjwIAy5S-A0130_assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP743085.RAEJ1y79uUCpSzYofU2UNhJJ_HmXfRgvoeVjwIAy5S-A0130_provenance.
• NP917872.RAvKzaSQVwW8WuVr7xUBFTtfvHLul2gXZ3OeVg7yeAsuM130_assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP917872.RAvKzaSQVwW8WuVr7xUBFTtfvHLul2gXZ3OeVg7yeAsuM130_provenance.
• NP178684.RAF3iLqinsGw4eifgMLSNcfWZM81MVZzhr9yinlm4fkDk130_assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP178684.RAF3iLqinsGw4eifgMLSNcfWZM81MVZzhr9yinlm4fkDk130_provenance.
• NP177893.RAI-4hvu9lj8kd1vYDKAtB-3Es6rYehCZIMR-fRdPIFz0130_assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP177893.RAI-4hvu9lj8kd1vYDKAtB-3Es6rYehCZIMR-fRdPIFz0130_provenance.
• NP414415.RAP3sj6acLjtxu3xsuGifU40m-8LDwZTUv2AxUqy51tnU130_assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP414415.RAP3sj6acLjtxu3xsuGifU40m-8LDwZTUv2AxUqy51tnU130_provenance.
• NP201518.RA0yLCkxekKVu8LnjpkKT6-9HZRxyjsxcONEBFwsxwAPY130_assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP201518.RA0yLCkxekKVu8LnjpkKT6-9HZRxyjsxcONEBFwsxwAPY130_provenance.
• NP201521.RA_6nCYxl17-1DU_HG3UwfzK3zr9X9aB5-pRgw4QMVgaU130_assertion description "[Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP201521.RA_6nCYxl17-1DU_HG3UwfzK3zr9X9aB5-pRgw4QMVgaU130_provenance.